Skip to main content
SpringerLink
Log in

Various Administration Forms of Nitrates and Their Possibilities

  • Section 1: Pharmacokinetics of Nitrates
  • Published:
Drugs Aims and scope Submit manuscript

Summary

This article reviews the development and pharmacokinetics of a number of new dosage formulations (e.g. transdermal patches and buccal tablets) and new active substances (e.g. isosorbide 5-mononitrate) which have recently been introduced to overcome some of the problems inherent in conventional formulations of organic nitrates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abrams J. Nitrate delivery systems in perspective. A decade of progress. American Journal of Medicine 76 (Suppl. 6a): 38–46, 1984

    Article  PubMed  CAS  Google Scholar 

  • Abrams J. New nitroglycerin formulations: transdermal and transmucosal nitroglycerin. Zeitschrift für Kardiologie 74 (Suppl. 4): 10–15, 1985

    PubMed  Google Scholar 

  • Abshagen U. Pharmacokinetics of ISDN, sustained-release ISDN and IS-5-MN. In Cohn & Rittinghausen (Eds) Mononitrates, pp. 53–66, Springer Verlag, Berlin, 1985

    Chapter  Google Scholar 

  • Bogentoft C, Sjögren J. Controlled release from dosage forms. In Breimer (Ed.) Towards better safety of drugs and pharmaceutical products, pp. 229–246, Elsevier/North-Holland Biomedical Press, Amsterdam, 1980

    Google Scholar 

  • Charash B, Scheldt SS. The controversy over transdermal nitroglycerin: an update. American Heart Journal 112: 207–215, 1986

    Article  PubMed  CAS  Google Scholar 

  • Erb R, Stoltman W. Evaluation of two nitroglycerin dosage forms. A metered spray and a soft gelatin capsule. Journal of Pharmacokinetics and Biopharmaceutics 6: 611–621, 1983

    Google Scholar 

  • Evans L, Spelman M. The problem of non-compliance with drug therapy. Drugs 25: 63–76, 1983

    Article  PubMed  CAS  Google Scholar 

  • Fung H-L. Nitrate formulations and drug delivery systems —an overview. Zeitschrift für Kardiologie 74 (Suppl. 4): 4–9, 1985

    PubMed  CAS  Google Scholar 

  • Gatlin KA. Comparative patient preference for 2 transdermal nitroglycerin patches. Current Therapeutic Research 38: 733–737, 1985

    Google Scholar 

  • Heidemann R, Menke G, Letzel H, Rietbrock N. Serumkonzentration von Glyceroltrinitrat (GTN) bei transdermalen Applikation von GTN-Pflastern unterschiedlicher Provenienz. Deutsche Medizinische Wochenschrift 110: 1568–1572, 1985

    Article  PubMed  CAS  Google Scholar 

  • Knoch A, Merkle HP. Theorie und Praxis transdermaler Freigabesysteme. Acta Pharmaceutica Technologica 31: 197–209, 1985

    Google Scholar 

  • Leeson LJ, Adair D, Clevenger J, Chiang N. The in vitro development of extended-release solid oral dosage forms. Journal of Pharmacokinetics and Biopharmaceutics 13: 493–514, 1985

    PubMed  CAS  Google Scholar 

  • McAllister A, Mosberg H, Settlage JA, Steiner JA. Plasma levels of nitroglycerin generated by three nitroglycerin patch preparations, Nitradisc, Transiderm-Nitro and Nitro-Dur and one ointment formulation, Nitrobid. British Journal of Clinical Pharmacology 21: 365–369, 1986

    Article  PubMed  CAS  Google Scholar 

  • Nigam R, Loveday BJ, Grainger SL, Maxton DG. Three times daily or 8-hourly. Journal of the Royal Society of Medicine 79: 15–16, 1986

    PubMed  CAS  Google Scholar 

  • Noonan PK, Gonzales MA, Ruggirello D, Tomlinson J, Babcock-Atkinson E, et al. Relative bioavailability of a new transdermal nitroglycerin delivery system. Journal of Pharmaceutical Sciences 75: 688–691, 1986

    Article  PubMed  CAS  Google Scholar 

  • Parikh NH, Babar A, Plakogiannis FM. Transdermal therapeutic systems (part 1). Pharmaceutica Acta Helvetica 59: 290–292, 1984

    CAS  Google Scholar 

  • Parikh NH, Babar A, Plakogiannis FM. Transdermal therapeutic systems (part 2). Pharmaceutica Acta Helvetica 60: 34–38, 1985

    CAS  Google Scholar 

  • Parker JO. Nitrate tolerance. American Journal of Cardiology 56: 281–311, 1985

    Article  Google Scholar 

  • Parker JO, Vankonghnett KA, Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose-response relation. American Journal of Cardiology 57: 1–5, 1986

    Article  PubMed  CAS  Google Scholar 

  • Prescott LF, Nimmo WD (Eds). Rate control in drug therapy, Churchill Livingstone, Edinburgh, 1985

  • Shah VP, Tymes NW, Yamamoto LA, Skelly JP. In vitro dissolution profile of transdermal nitroglycerin patches using paddle method. International Journal of Pharmaceutics 32: 243–250, 1986

    Article  CAS  Google Scholar 

  • Sjögren J. Studies on a sustained release principle based on an inert plastic matrix. Acta Pharmaceutica Suecia 8: 153–168, 1971

    Google Scholar 

  • Sjögren J. Controlled release oral formulation technology. In Prescott & Nimmo (Eds) Rate control in drug therapy, pp. 38–47, Churchill Livingstone, Edinburgh, 1985

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical R & D, AB Hassle, S-431 83, Mölndal, Sweden

    U. E. Jonsson

Authors
  1. U. E. Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonsson, U.E. Various Administration Forms of Nitrates and Their Possibilities. Drugs 33 (Suppl 4), 23–31 (1987). https://doi.org/10.2165/00003495-198700334-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198700334-00006

Keywords

Search

Navigation